Although serum IgE levels started to raise again between each IA cycle and in the 20‐week follow‐up period, this intervention was accompanied by a clinically relevant amelioration of AD severity scores (peek reduction in SCORAD and EASI by 35% and 52% form baseline, respectively). Here, IGHE is linked to Alzheimer disease.